51 stories found
As closing arguments approach in the Lindsay Clancy murder trial, Candace Owens has publicly defended Clancy, asserting her innocence and blaming 'big pharma' for inducing 'intentional psychosis.' A psychiatrist known for supporting insanity defenses is also set to testify for Clancy.
Kailera Therapeutics has achieved a record-breaking initial public offering in the obesity treatment sector, making it a significant development that major pharmaceutical companies cannot afford to overlook.
A potential partnership between Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD) is being explored as a possible new engine for growth in the pharmaceutical industry.
Reports of preliminary discussions between pharmaceutical giants AstraZeneca and Bristol Myers Squibb regarding a potential acquisition have been denied, clarifying earlier speculation over consolidation in the Big Pharma sector.
An analysis suggests that while Big Pharma companies are acquiring growth, Novartis is strategically betting on its internal drug development pipeline for future expansion.
Eli Lilly's acquisition of psychedelic drug maker AtaiBeckley signals a significant 'buy signal' for the market of psychedelic drugs aimed at treating mental health conditions, marking Big Pharma's growing acceptance of these previously stigmatized medications.
A trend of major pharmaceutical companies investing in psychedelic drugs is emerging, with Eli Lilly making a significant deal worth up to $3.8 billion with AtaiBeckley, signaling a potential buyout spree in the sector.
JPMorgan bankers report that mergers and acquisitions in the pharmaceutical sector continue to outpace initial public offerings in the biotechnology industry.
The U.S. Supreme Court rejected appeals from major pharmaceutical companies, including Eli Lilly, challenging both a Civil War-era whistleblower law related to Medicaid fraud and the Biden administration's Medicare drug price negotiation program. This decision upholds government efforts to control drug costs and combat fraud.
An analysis highlights the five hottest biotech hunting grounds for Big Pharma, identifying the category leaders in these promising areas for pharmaceutical innovation and investment.
Dozens of UK Members of Parliament are opposing Health Secretary Wes Streeting's move to grant himself power to dictate NHS drug prices, raising concerns about legality and potential benefits for big pharmaceutical companies.
Major pharmaceutical companies are focusing on smaller deals, a strategic shift that is proving advantageous for the biotechnology sector.
Former President Trump has imposed 100% tariffs on prescription drugs from companies that have not agreed to lower prices, a move aimed at incentivizing domestic production and reducing drug costs in the United States.
Poolbeg Pharma's CEO stated that the recent patent win for POLB-001 significantly strengthens the company's potential for partnerships with major pharmaceutical companies.
AbbVie is highlighted as the only big pharma stock considered a 'buy-and-never-sell' option by an analyst.
An analysis suggests that pharmaceutical giant Novartis could be a stable, long-term core holding for investors.
Aging means “becoming a target” of the industry, one expert said. After decades of debate, politicians of all stripes are proposing bans.
A report claims that nearly 14 years before COVID-19, seven federal agencies and major pharmaceutical companies quietly established a 'Pandemic-Industrial Complex' through the creation of the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) by HHS.
Major pharmaceutical companies are cautioning that Germany's plans to impose higher mandatory discounts for insurers, aimed at saving €12 billion by 2030, will ultimately backfire.
An article suggests that Revolution Medicines could become the next acquisition target for a major pharmaceutical company, highlighting its strategic value.
AstraZeneca's stock fell significantly following market rumors of a potential $400 billion merger with Bristol Myers Squibb. Investors and analysts expressed skepticism about the strategic logic and potential benefits of such a large-scale pharmaceutical tie-up.
The biotechnology sector is experiencing a record surge in deals as major pharmaceutical companies, concerned about expiring patents on lucrative drugs, aggressively pursue new blockbuster medicines.
An analysis explores why major pharmaceutical companies are unlikely to develop affordable anti-aging drugs, despite scientific hypotheses suggesting generic drugs like metformin and rapamycin could slow aging.
Major pharmaceutical companies are seeing gains as the U.S. government considers reducing discounts under the 340B drug pricing program.
Top bankers indicate that while the biotech IPO window is beginning to open, mergers and acquisitions by large pharmaceutical companies remain the primary driver of dealmaking, fueled by the need to replenish drug pipelines ahead of patent expirations.
Senator Bill Cassidy, who voted to convict former President Trump, was unseated in the Louisiana Republican primary by a challenger endorsed by Donald Trump. This defeat is seen by many as a significant demonstration of Trump's continued influence over the Republican Party.
Advances are transforming cancer treatment, but questions are being raised about whether major pharmaceutical companies can afford to implement these revolutionary changes. The financial implications of new therapies pose a significant challenge for the industry.
An article argues that the pursuit of a cancer cure should not be constrained by the interests and influence of large pharmaceutical companies.
Major pharmaceutical companies are increasingly turning their attention to China as a source for the newest drug ideas and innovations.
As mergers and acquisitions in the oncology sector intensify, five biotech companies are identified as potential targets for acquisition by larger pharmaceutical firms.
An official from the Federal Trade Commission (FTC) stated that the agency is monitoring how major pharmaceutical companies are reacting to upcoming patent expirations.
Watch: RFK Jr. Destroys Media's Trump Caricature, Celebrates Epic Win On Drug Prices Authored by Steve Watson via Modernity.news, HHS Secretary Robert F. Kennedy Jr. delivered a powerful takedown of the fake news narrative surrounding President Trump, exposing the blatant lies and highlighting the administration’s groundbreaking success in driving down prescription drug costs—a move that puts American families first and crushes Big Pharma’s grip. Kennedy’s remarks come amid t...
The Wall Street Journal likens the disruptive effect of Ozempic on the pharmaceutical industry to the 'Napster moment' for music, highlighting its significant market impact.
The pharmaceutical sector is increasingly optimistic about the future of weight-loss treatments, with a significant shift from injectable medications to more accessible pill forms, potentially expanding the market to $200 billion by the decade's end.
Pharmaceutical companies are actively developing a new generation of GLP-1 medicines for weight loss, aiming to create drugs with fewer side effects as some existing patents begin to expire.
An expert suggests that the future growth of major pharmaceutical companies may increasingly depend on advancements in Chinese science, stating that 'We Can't Ban Our Way Out of This'.
An article explores the current and future prospects for mergers and acquisitions within the Big Pharma industry.
Vertex has completed a $10 billion acquisition of Crinetics, leading to speculation that Viking Therapeutics could be the next major pharmaceutical company to be targeted for a takeover.
Major pharmaceutical companies are investing in the development of drugs based on hallucinogenic substances, including toad venom and psychedelic mushrooms, with the Donald Trump administration reportedly giving the green light for these new medications.
Eli Lilly is set to acquire AtaiBeckley for a sum of up to $3.8 billion, marking the latest venture by a major pharmaceutical company into the psychedelic drug market.
Tulsi Gabbard has released what she claims is evidence suggesting Dr. Anthony Fauci lied to Congress regarding the funding of "risky" coronavirus research linked to Big Pharma.
Biotech mergers and acquisitions are experiencing a strong start in 2026, poised for their best year since before the Covid-19 pandemic, driven by looming patent cliffs, buoyant public markets, and Big Pharma's pipeline expansion efforts.
An Iraqi commander linked to Iran-backed Kataib Hezbollah was arrested in Turkey and transferred to the US, where he faces charges for allegedly planning attacks on American interests and Jewish sites in the Netherlands. US authorities suspect him of organizing various plots.
An analysis explores whether Bristol Myers Squibb represents the best value investment among major pharmaceutical companies. The article likely delves into the company's financials, pipeline, and market position.
Big Pharma companies are increasingly focusing on smaller acquisitions and disciplined pricing, a trend that is proving to be advantageous for a wider range of biotech firms.
Major pharmaceutical companies involved with COVID vaccines were compelled to discontinue a new research study because of insufficient participant enrollment.
Ireland has become the world's third-largest exporter of pharmaceuticals, with medicines accounting for about 20% of its GDP, raising concerns about the risks associated with this dependency amid potential tariffs.
AP Shills For Big Pharma Antidepressants With 'Bewildering' Hit Piece Check this out... The Trump FDA's top drug regulator, Dr.
Big pharma has emerged from its 2025 paralysis with plenty of firepower
How Ozempic Brought a Napster Moment to Big Pharma The Wall Street Journal
The weight-loss drug market is rapidly expanding globally, with a shift from injections to pills and intense competition between pharmaceutical giants like Novo Nordisk and Eli Lilly. Regulatory scrutiny is also impacting new product offerings in this lucrative sector.